Skip Nav Destination
Drug Discovery
Designing Multi-Target Drugs
Hardback ISBN:
978-1-84973-362-5
PDF ISBN:
978-1-84973-491-2
Special Collection:
2012 ebook collection
,
2011-2015 industrial and pharmaceutical chemistry subject collection
Series:
Drug Discovery Series
No. of Pages:
394
Published online:
28 Mar 2012
Published in print:
12 Apr 2012
About this book
Multi-target drug discovery (MTDD) is an emerging area of increasing interest to the drug discovery community. Drugs that modulate several targets have the potential for an improved balance of efficacy and safety compared to single targets agents. Although there are a number of marketed drugs that are thought to derive their therapeutic benefit by virtue of interacting with multiple targets, the majority of these were discovered accidentally. Written by world renowned experts, this is the first book to gather together knowledge and experiences of the rational discovery of multi-target drugs. It describes the current state of the art, the achievements and the challenges of the field and importantly the lessons learned by researchers to date and their application to future MTDD.
Designing Multi-Target Drugs, The Royal Society of Chemistry, 2012.
Download citation file:
Digital access
$216.00
Print format
Designing Multi-Target Drugs
$216.00
Table of contents
-
Chapter 1: Simple Drugs Do Not Cure Complex Diseases: The Need for Multi-Targeted Drugsp1-13ByJorrit J. HornbergJorrit J. HornbergSearch for other works by this author on:
-
Chapter 2: Clinical Need and Rationale for Multi-Target Drugs in Psychiatryp14-31ByMohammed ShahidMohammed ShahidSearch for other works by this author on:
-
Chapter 3: Drug Molecules and Biology: Network and Systems Aspectsp32-49ByMalcolm P. Young;Malcolm P. YoungInstitute of NeuroscienceNewcastle UniversityNE2 4HHUKSearch for other works by this author on:Alan V. WhitmoreAlan V. WhitmoreSchool of PharmacyUniversity of LondonBrunswick Square, London WC1N 1AXUKSearch for other works by this author on:
-
Chapter 4: Chemoinformatic Approaches to Target Identificationp50-65ByElisabet Gregori-Puigjané;Elisabet Gregori-PuigjanéUCSF Department of Pharmaceutical ChemistryUCSF MC 2550, 1700 4th St, San FranciscoCA 94158USASearch for other works by this author on:Michael J. KeiserMichael J. KeiserUCSF Department of Pharmaceutical ChemistryUCSF MC 2550, 1700 4th St, San FranciscoCA 94158USASeaChange Pharmaceuticals Inc.QB3 MC 2522, 1700 4th St Ste 214, San FranciscoCA 94158-2330USA[email protected]Search for other works by this author on:
-
Chapter 5: Designing Multi-Target Drugs: In Vitro Panel Screening – Biological Fingerprintingp66-85ByJonathan S. MasonJonathan S. MasonHeptares Therapeutics LtdBioPark, Broadwater Road, Welwyn Garden City, AL7 3AX, UK & Lundbeck ResearchOttiliavej 9, Valby, DK-2500Denmark[email protected]Search for other works by this author on:
-
Chapter 6: Phenotypic and In Vivo Screening: Lead Discovery and Drug Repurposingp86-93ByChristopher A. LipinskiChristopher A. LipinskiSearch for other works by this author on:
-
Chapter 7: Target/s Identification Approaches – Experimental Biological Approachesp94-110ByGiulio Superti-Furga;Giulio Superti-FurgaCeMM – Research Centre for Molecular Medicine of the Austrian Academy of SciencesLazarettgasse 14/AKH BT 25.3A-1090 ViennaAustria[email protected]Search for other works by this author on:Kilian Huber;Kilian HuberCeMM – Research Centre for Molecular Medicine of the Austrian Academy of SciencesLazarettgasse 14/AKH BT 25.3A-1090 ViennaAustria[email protected]Search for other works by this author on:Georg WinterGeorg WinterCeMM – Research Centre for Molecular Medicine of the Austrian Academy of SciencesLazarettgasse 14/AKH BT 25.3A-1090 ViennaAustria[email protected]Search for other works by this author on:
-
Chapter 8: Historical Strategies for Lead Generationp111-129ByJ. Richard MorphyJ. Richard MorphySearch for other works by this author on:
-
Chapter 9: In Silico Lead Generation Approaches in Multi-Target Drug Discoveryp130-140ByXiaohou Ma;Xiaohou MaBioinformatics and Drug Design GroupDepartment of Pharmacy, Centre for Computational Science and Engineering, National University of SingaporeBlk S16, Level 8, 3 Science Drive 2Singapore 117543[email protected]Search for other works by this author on:Yuzong ChenYuzong ChenBioinformatics and Drug Design GroupDepartment of Pharmacy, Centre for Computational Science and Engineering, National University of SingaporeBlk S16, Level 8, 3 Science Drive 2Singapore 117543[email protected]Search for other works by this author on:
-
Chapter 10: The Challenges of Multi-Target Lead Optimizationp141-154ByJ. Richard MorphyJ. Richard MorphySearch for other works by this author on:
-
Chapter 11: Combination Agents Versus Multi-Targeted Agents – Pros and Consp155-180ByJose G. Monzon;Jose G. MonzonNational Cancer Institute of CanadaClinical Trials Group10 Stuart Street, Kingston, ON K7L 3N6Canada[email protected]Search for other works by this author on:Janet DanceyJanet DanceyNational Cancer Institute of CanadaClinical Trials Group10 Stuart Street, Kingston, ON K7L 3N6Canada[email protected]Search for other works by this author on:
-
Chapter 12: The Discovery of Lapatinibp181-205ByKaren E. LackeyKaren E. LackeySearch for other works by this author on:
-
Chapter 13: Identification and Optimization of Dual PI3K/mTOR Inhibitorsp206-220ByAndreas Karlsson;Andreas KarlssonStructureDesignand InformaticsSearch for other works by this author on:Carlos García-EcheverríaCarlos García-EcheverríaOncology Drug Discovery and Preclinical ResearchSanofi-Aventis, Vitry-sur-SeineFrance[email protected]Search for other works by this author on:
-
Chapter 14: Discovery of HDAC-Inhibiting Multi-Target Inhibitorsp221-242ByChanggeng QianChanggeng QianSearch for other works by this author on:
-
Chapter 15: Targeting Protein–Protein Interactions: Dual Inhibitors of Bcl-2 and Bcl-xLp243-262ByMichael D. WendtMichael D. WendtOncology Research, Global Pharmaceutical Research and DevelopmentAbbott Laboratories100 Abbott Park Road, Abbott Park, IL 60064USA[email protected]Search for other works by this author on:
-
Chapter 16: Discovery of the Anti-Psychotic Drug, Ziprasidonep263-269ByJohn A. Lowe, IIIJohn A. Lowe, IIISearch for other works by this author on:
-
Chapter 17: The Rational Design of Triple Reuptake Inhibitors for the Treatment of Depressionp270-289ByRobert J. WeikertRobert J. WeikertSearch for other works by this author on:
-
Chapter 18: Discovery of Multi-Target Agents for Neurological Diseases via Ligand Designp290-315ByMaria Laura Bolognesi;Maria Laura BolognesiUniversity of BolognaItalySearch for other works by this author on:Carlo Melchiorre;Carlo MelchiorreUniversity of BolognaItalySearch for other works by this author on:Cornelis J. Van der Schyf;Cornelis J. Van der SchyfNortheast Ohio Medical University (NEOMED)Rootstown, OHUSASearch for other works by this author on:Moussa YoudimMoussa YoudimSearch for other works by this author on:
-
Chapter 19: Designing Drugs with Dual Activity: Novel Dual Angiotensin II and Endothelin Receptor Antagonistsp316-334ByNatesan MurugesanNatesan MurugesanDepartment of Medicinal ChemistryBristol-Myers Squibb Research and DevelopmentPrincetonNJ 08543-5400, USA[email protected]Search for other works by this author on:
-
Chapter 20: Ethyl Urea Inhibitors of the Bacterial Type II Topoisomerases DNA Gyrase (GyrB) and Topoisomerase IV (ParE)p335-352ByStephen P. East;Stephen P. EastEvotec (UK) Ltd114 Milton Park, AbingdonOxfordshire, OX14 4SAUKSearch for other works by this author on:Lloyd G. Czaplewski;Lloyd G. CzaplewskiBiota Europe LimitedBegbroke Business & Science Park, Sandy Lane, Yarnton, OxfordshireOX5 1PFUK[email protected]Search for other works by this author on:David J. HaydonDavid J. HaydonBiota Europe LimitedBegbroke Business & Science Park, Sandy Lane, Yarnton, OxfordshireOX5 1PFUK[email protected]Search for other works by this author on:
Spotlight
Advertisement
Advertisement
